Search research articles
Contact Us
Filters
Showing results (11-20 of 19) with videos related to
Page
of 2
Sort By:
You have reached the last page of results.
This site can display upto 19 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 10, 2025
Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!
Emmanuel Deshayes, Ioannis Karfis, Lore Santoro, et al.
EJNMMI Research
|
November 18, 2024
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study
Rachele Danieli, Magdalena Mileva, Gwennaëlle Marin, et al.
Clinical Nuclear Medicine
|
June 24, 2024
177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study
Magdalena Mileva, Camille Van Bogaert, Gwennaëlle Marin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 22, 2025
[<sup>18</sup>F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study
David L Chan, Aimee Hayes, Ioannis Karfis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2024
[<sup>18</sup>F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
David L Chan, Aimee R Hayes, Ioannis Karfis, et al.
British Journal of Cancer
|
November 26, 2022
Dual [<sup>68</sup>Ga]DOTATATE and [<sup>18</sup>F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
David L Chan, Aimee R Hayes, Ioannis Karfis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2024
Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Mattia Rediti, Danai Fimereli, Magdalena Mileva, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2024
Prediction of <sup>177</sup>Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, et al.
NPJ Breast Cancer
|
January 6, 2024
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)
Magdalena Mileva, Elisabeth G E de Vries, Thomas Guiot, et al.
Page
of 2
Search research articles
Search
Showing results (11-20 of 19) with videos related to
Sort By:
Page
of 2
You have reached the last page of results.
This site can display upto 19 results.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
April 10, 2025
Patient-Specific Dosimetry-Driven PRRT: Time to Move Forward!
Emmanuel Deshayes, Ioannis Karfis, Lore Santoro, et al.
EJNMMI Research
|
November 18, 2024
Evolution of dosimetric parameters through PRRT and potential impact on clinical practice: data from the prospective phase II LUMEN study
Rachele Danieli, Magdalena Mileva, Gwennaëlle Marin, et al.
Clinical Nuclear Medicine
|
June 24, 2024
177 Lu-DOTATATE PRRT Safety and Organ-at-Risk Dosimetry in Patients With Gastroenteropancreatic Neuroendocrine Tumors : Data From the Prospective Phase 2 LUMEN Study
Magdalena Mileva, Camille Van Bogaert, Gwennaëlle Marin, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
May 22, 2025
[<sup>18</sup>F]FDG Metabolic Tumor Volume as a Prognostic Marker in Neuroendocrine Neoplasm: A Multicenter Study
David L Chan, Aimee Hayes, Ioannis Karfis, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2024
[<sup>18</sup>F]FDG PET/CT-Avid Discordant Volume as a Biomarker in Patients with Gastroenteropancreatic Neuroendocrine Neoplasms: A Multicenter Study
David L Chan, Aimee R Hayes, Ioannis Karfis, et al.
British Journal of Cancer
|
November 26, 2022
Dual [<sup>68</sup>Ga]DOTATATE and [<sup>18</sup>F]FDG PET/CT in patients with metastatic gastroenteropancreatic neuroendocrine neoplasms: a multicentre validation of the NETPET score
David L Chan, Aimee R Hayes, Ioannis Karfis, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 29, 2024
Integrating Molecular Imaging and Transcriptomic Profiling in Advanced HER2-Positive Breast Cancer Receiving Trastuzumab Emtansine: An Analysis of the ZEPHIR Clinical Trial
Mattia Rediti, Danai Fimereli, Magdalena Mileva, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2024
Prediction of <sup>177</sup>Lu-DOTATATE PRRT Outcome Using Multimodality Imaging in Patients with Gastroenteropancreatic Neuroendocrine Tumors: Results from a Prospective Phase II LUMEN Study
Magdalena Mileva, Gwennaëlle Marin, Hugo Levillain, et al.
NPJ Breast Cancer
|
January 6, 2024
Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial)
Magdalena Mileva, Elisabeth G E de Vries, Thomas Guiot, et al.
Page
of 2